Skip to main content

House Dust Mite Allergy

3
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Allergopharma
AllergopharmaGermany - Reinbek
1 program
1
house dust mite allergen extractPhase 41 trial
Active Trials
NCT00263549CompletedEst. Feb 2006
Inmunotek
InmunotekSpain - Madrid
1 program
1
MM09 allergoid-mannan conjugates subcutaneousPhase 31 trial
Active Trials
NCT05400811Unknown400Est. Jul 2025
Ergomed
ErgomedUK - Guildford
1 program
1
PURETHAL Mites 50,000 AUeq/mlPhase 31 trial
Active Trials
NCT06920771Active Not Recruiting552Est. Aug 2026
Hal Allergy
Hal AllergyNetherlands - Leiden
2 programs
SUBLIVAC FIX Mite mixturePHASE_1_2
PURETHAL Mites 50,000 AUeq/mlPHASE_3

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Allergopharmahouse dust mite allergen extract
ErgomedPURETHAL Mites 50,000 AUeq/ml
InmunotekMM09 allergoid-mannan conjugates subcutaneous

Clinical Trials (3)

Total enrollment: 952 patients across 3 trials

NCT00263549Allergopharmahouse dust mite allergen extract

Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis

Start: Sep 2002Est. completion: Feb 2006
Phase 4Completed
NCT06920771ErgomedPURETHAL Mites 50,000 AUeq/ml

A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

Start: Sep 2024Est. completion: Aug 2026552 patients
Phase 3Active Not Recruiting
NCT05400811InmunotekMM09 allergoid-mannan conjugates subcutaneous

Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis

Start: Dec 2022Est. completion: Jul 2025400 patients
Phase 3Unknown

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.